Methods for reducing LRRK2 expression
AssigneeIonis Pharmaceuticals, Inc.
InventorsHien Thuy Zhao, Holly Kordasiewicz
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for decreasing LRRK2 mRNA expression. Such methods are useful to ameliorate LRRK2 associated diseases. Such LRRK2 associated diseases include Parkinson's Disease, including non-LRRK2 mediated Parkinson's Disease.
Claims25
A method comprising administering to an animal having Parkinson's disease an oligomeric compound comprising a modified oligonucleotide, wherein the animal has a causative LRRK2 genetic mutation for Parkinson's disease, and wherein the modified oligonucleotide:
- a) consists of 12 to 30 linked nucleosides;
- b) has a nucleobase sequence that is at least 90% complementary to the nucleobase sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 3;
- and
- c) comprises at least one modified nucleoside comprising a modified sugar moiety and/or at least one modified internucleoside linkage,
- wherein the administering results in amelioration of a symptom of Parkinson's disease,
- wherein the symptom is aggregate formation or reduced motor function.
A method comprising identifying an animal having Parkinson's disease wherein the animal has a causative LRRK2 genetic mutation for Parkinson's disease, and administering to the animal an oligomeric compound comprising a modified oligonucleotide, wherein the modified oligonucleotide:
- a) consists of 12 to 30 linked nucleosides;
- b) has a nucleobase sequence that is at least 90% complementary to the nucleobase sequence of SEQ ID NO:
- 2 or SEQ ID NO:
- 3;
- and
- c) comprises at least one modified nucleoside comprising a modified sugar moiety and/or at least one modified internucleoside linkage,
- wherein the administering results in amelioration of a symptom of Parkinson's disease,
- wherein the symptom is aggregate formation or reduced motor function.
Dependencies are inferred from the claim text.